Within the framework of the Board's established strategy, a significant milestone was recently communicated with the sale of Druglog to
The work of looking for and identifying potential acquisitions will be done systematically and started immediately. The focus will be on looking for niche and unlisted businesses in medical technology and pharmaceuticals. Furthermore, the companies must have a history of profitability.
In parallel with investigating the new business direction, the strategy is also underway to divest Wastelog, a product that for many years has had greater sales success than Druglog, not least in the US market. Pharmacolog is in ongoing discussions with potential buyers regarding Wastelog. A successful sale of Wastelog would further strengthen the company's financial position and the conditions to execute on the possible new business direction.
For more information contact:
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog's products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by
Further information regarding the company is available at https://pharmacolog.com/.
The company's Certified Adviser is
https://news.cision.com/pharmacolog/r/pharmacolog-investigates-the-possibilities-for-a-new-business-direction,c3928915
https://mb.cision.com/Main/12317/3928915/2605541.pdf
https://news.cision.com/pharmacolog/i/pharmacolog-news-500x388px-100,c3267652
(c) 2024 Cision. All rights reserved., source